CoChat

First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis

Open access
Wang, Rui, Li, Wentao, Bordewijk, Esmée M, Legro, Richard S, Zhang, Heping, Wu, Xiaoke, Gao, Jingshu, Morin-Papunen, Laure, Homburg, Roy, König, Tamar E, Moll, Etelka, Kar, Sujata, Huang, Wei, Johnson, Neil P, Amer, Saad A, Vegetti, Walter, Palomba, Stefano, Falbo, Angela, Özmen, Ülkü, Nazik, Hakan, Williams, Christopher D, Federica, Grasso, Lord, Jonathan, Sahin, Yilmaz, Bhattacharya, Siladitya, Norman, Robert J, van Wely, Madelon, Mol, Ben Willem, Reproductive Medicine Network+, the International Ovulation Induction IPDMA Collaboration · 2019 · Human Reproduction Update
Cited by 137

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most frequent cause of anovulatory infertility. In women with PCOS, effective ovulation induction serves as an important first-line treatment for anovulatory infertility. Individual participant data (IPD) meta-analysis is considered as the gold standard for evidence synthesis which provides accurate assessments of outcomes from primary randomised controlled trials (RCTs) and allows additional analyses for time-to-event outcomes. It also facilitates treatment–covariate interaction analyses and therefore offers an opportunity for personalised medicine. OBJECTIVE AND RATIONALE: We aimed to evaluate the effectiveness of different ovulation induction agents, in particular letrozole alone and clomiphene citrate (CC) plus metformin, as compared to CC alone, as the first-line choice for ovulation induction in women with PCOS and infertility, and to explore interactions between treatment and participant-level baseline characteristics. SEARCH METHODS: We searched electronic databases including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials up to 20 December 2018. We included RCTs comparing the following interventions with each other or placebo/no treatment in women with PCOS and infertility: CC, metformin, CC plus metformin, letrozole, gonadotrophin and tamoxifen. We excluded studies on treatment-resistant women. The primary outcome was live birth. We contacted the investigators of eligible RCTs to share the IPD and performed IPD meta-analyses. We assessed the risk of bias by using the Cochrane risk of bias tool for RCTs. OUTCOMES: IPD of 20 RCTs including 3962 women with PCOS were obtained. Six RCTs compared letrozole and CC in 1284 women. Compared with CC, letrozole improved live birth rates (3 RCTs, 1043 women, risk ratio [RR] 1.43, 95% confidence interval [CI] 1.17–1.75, moderate-certainty evidence) and clinical pregnancy rates (6 RCTs, 1284 women, RR 1.45, 95% CI 1.23–1.70, moderate-certainty evidence) and reduced time-to-pregnancy (6 RCTs, 1235 women, hazard ratio [HR] 1.72, 95% CI 1.38–2.15, moderate-certainty evidence). Meta-analyses of effect modifications showed a positive interaction between baseline serum total testosterone levels and treatment effects on live birth (interaction RR 1.29, 95% CI 1.01–1.65). Eight RCTs compared CC plus metformin to CC alone in 1039 women. Compared with CC alone, CC plus metformin might improve clinical pregnancy rates (8 RCTs, 1039 women, RR 1.18, 95% CI 1.00–1.39, low-certainty evidence) and might reduce time-to-pregnancy (7 RCTs, 898 women, HR 1.25, 95% CI 1.00–1.57, low-certainty evidence), but there was insufficient evidence of a difference on live birth rates (5 RCTs, 907 women, RR 1.08, 95% CI 0.87–1.35, low-certainty evidence). Meta-analyses of effect modifications showed a positive interaction between baseline insulin levels and treatment effects on live birth in the comparison between CC plus metformin and CC (interaction RR 1.03, 95% CI 1.01–1.06). WIDER IMPLICATIONS: In women with PCOS, letrozole improves live birth and clinical pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be recommended as the preferred first-line treatment for women with PCOS and infertility. CC plus metformin may increase clinical pregnancy and may reduce time-to-pregnancy compared to CC alone, while there is insufficient evidence of a difference on live birth. Treatment effects of letrozole are influenced by baseline serum levels of total testosterone, while those of CC plus metformin are affected by baseline serum levels of insulin. These interactions between treatments and biomarkers on hyperandrogenaemia and insulin resistance provide further insights into a personalised approach for the management of anovulatory infertility related to PCOS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humupd/dmz029

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 137

Metadata

Authors
Wang, R., Li, W., Bordewijk, E. M., Legro, R. S., Zhang, H., Wu, X., Gao, J., Morin-Papunen, L., Homburg, R., König, T. E., Moll, E., Kar, S., Huang, W., Johnson, N. P., Amer, S. A., Vegetti, W., Palomba, S., Falbo, A., Özmen, Ü., Nazik, H., Williams, C. D., Federica, G., Lord, J., Sahin, Y., Bhattacharya, S., Norman, R. J., van Wely, M., Mol, B. W., Reproductive Medicine Network+, & the International Ovulation Induction IPDMA Collaboration
Venue
Human Reproduction Update
Published
2019-10-23
Volume
25
Issue
6
Pages
717-732
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W2981633327
Cited by
137
References
19
FWCI
2.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1093/humupd/dmz029
The paper
Wang, R., Li, W., Bordewijk, E. M., Legro, R. S., Zhang, H., Wu, X., Gao, J., Morin-Papunen, L., Homburg, R., König, T. E., Moll, E., Kar, S., Huang, W., Johnson, N. P., Amer, S. A., Vegetti, W., Palomba, S., Falbo, A., Özmen, Ü., . . . the International Ovulation Induction IPDMA Collaboration. (2019). First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Human Reproduction Update. https://doi.org/10.1093/humupd/dmz029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.